Hemodynamic markers of pulmonary vasculopathy for prediction of early right heart failure and mortality after heart transplantation.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
04 2023
Historique:
received: 30 04 2022
revised: 13 09 2022
accepted: 02 10 2022
medline: 29 3 2023
pubmed: 5 11 2022
entrez: 4 11 2022
Statut: ppublish

Résumé

Elevated pulmonary vascular resistance (PVR) is broadly accepted as an imminent risk factor for mortality after heart transplantation (HTx). However, no current HTx recipient risk score includes PVR or other hemodynamic parameters. This study examined the utility of various hemodynamic parameters for risk stratification in a contemporary HTx population. Patients from seven German HTx centers undergoing HTx between 2011 and 2015 were included retrospectively. Established risk factors and complete hemodynamic datasets before HTx were analyzed. Outcome measures were overall all-cause mortality, 12-month mortality, and right heart failure (RHF) after HTx. The final analysis included 333 patients (28% female) with a median age of 54 (IQR 46-60) years. The median mean pulmonary artery pressure was 30 (IQR 23-38) mm Hg, transpulmonary gradient 8 (IQR 5-10) mm Hg, and PVR 2.1 (IQR 1.5-2.9) Wood units. Overall mortality was 35.7%, 12-month mortality was 23.7%, and the incidence of early RHF was 22.8%, which was significantly associated with overall mortality (log-rank HR 4.11, 95% CI 2.47-6.84; log-rank p < .0001). Pulmonary arterial elastance (Ea) was associated with overall mortality (HR 1.74, 95% CI 1.25-2.30; p < .001) independent of other non-hemodynamic risk factors. Ea values below a calculated cutoff represented a significantly reduced mortality risk (HR 0.38, 95% CI 0.19-0.76; p < .0001). PVR with the established cutoff of 3.0 WU was not significant. Ea was also significantly associated with 12-month mortality and RHF. Ea showed a strong impact on post-transplant mortality and RHF and should become part of the routine hemodynamic evaluation in HTx candidates.

Sections du résumé

BACKGROUND
Elevated pulmonary vascular resistance (PVR) is broadly accepted as an imminent risk factor for mortality after heart transplantation (HTx). However, no current HTx recipient risk score includes PVR or other hemodynamic parameters. This study examined the utility of various hemodynamic parameters for risk stratification in a contemporary HTx population.
METHODS
Patients from seven German HTx centers undergoing HTx between 2011 and 2015 were included retrospectively. Established risk factors and complete hemodynamic datasets before HTx were analyzed. Outcome measures were overall all-cause mortality, 12-month mortality, and right heart failure (RHF) after HTx.
RESULTS
The final analysis included 333 patients (28% female) with a median age of 54 (IQR 46-60) years. The median mean pulmonary artery pressure was 30 (IQR 23-38) mm Hg, transpulmonary gradient 8 (IQR 5-10) mm Hg, and PVR 2.1 (IQR 1.5-2.9) Wood units. Overall mortality was 35.7%, 12-month mortality was 23.7%, and the incidence of early RHF was 22.8%, which was significantly associated with overall mortality (log-rank HR 4.11, 95% CI 2.47-6.84; log-rank p < .0001). Pulmonary arterial elastance (Ea) was associated with overall mortality (HR 1.74, 95% CI 1.25-2.30; p < .001) independent of other non-hemodynamic risk factors. Ea values below a calculated cutoff represented a significantly reduced mortality risk (HR 0.38, 95% CI 0.19-0.76; p < .0001). PVR with the established cutoff of 3.0 WU was not significant. Ea was also significantly associated with 12-month mortality and RHF.
CONCLUSIONS
Ea showed a strong impact on post-transplant mortality and RHF and should become part of the routine hemodynamic evaluation in HTx candidates.

Identifiants

pubmed: 36333208
pii: S1053-2498(22)02168-4
doi: 10.1016/j.healun.2022.10.002
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

512-521

Informations de copyright

Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Auteurs

Andreas J Rieth (AJ)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany, German Center for Cardiovascular Research (DZHK), Frankfurt am Main, Germany. Electronic address: a.rieth@kerckhoff-klinik.de.

Rasmus Rivinius (R)

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany, German Center for Cardiovascular Research (DZHK), Heidelberg/Mannheim, Germany.

Tom Lühring (T)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany, German Center for Cardiovascular Research (DZHK), Frankfurt am Main, Germany.

Dimitri Grün (D)

Department of Cardiology, Justus Liebig University Giessen, Giessen, Germany.

Till Keller (T)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany, German Center for Cardiovascular Research (DZHK), Frankfurt am Main, Germany; Department of Cardiology, Justus Liebig University Giessen, Giessen, Germany.

Carola Grinninger (C)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Dominik Schüttler (D)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Christoph L Bara (CL)

Department of Cardiac, Thorax, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

Matthias Helmschrott (M)

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany, German Center for Cardiovascular Research (DZHK), Heidelberg/Mannheim, Germany.

Norbert Frey (N)

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany, German Center for Cardiovascular Research (DZHK), Heidelberg/Mannheim, Germany.

Tim Sandhaus (T)

Department of Cardiac Surgery, University Hospital Jena, Jena, Germany.

Christian Schulze (C)

Department of Cardiology, University Hospital Jena, Jena, Germany.

Steffen Kriechbaum (S)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany, German Center for Cardiovascular Research (DZHK), Frankfurt am Main, Germany.

Julia Vietheer (J)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany, German Center for Cardiovascular Research (DZHK), Frankfurt am Main, Germany.

Jürgen Sindermann (J)

Department of Cardiology, Münster University Hospital, Münster, Germany; Department of Rehabilitation, Schüchtermann Clinic, Bad Rothenfelde, Germany.

Henryk Welp (H)

Department of Cardiac Surgery, Münster University Hospital, Münster, Germany.

Artur Lichtenberg (A)

Department of Cardiac Surgery, Düsseldorf University Hospital, Düsseldorf, Germany.

Yeong-Hoon Choi (YH)

Department of Cardiac Surgery, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

Manfred Richter (M)

Department of Cardiac Surgery, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

Khodr Tello (K)

Department of Internal Medicine, Justus Liebig University Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.

Manuel J Richter (MJ)

Department of Internal Medicine, Justus Liebig University Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany; Department of Pneumology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

Christian W Hamm (CW)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany, German Center for Cardiovascular Research (DZHK), Frankfurt am Main, Germany; Department of Cardiology, Justus Liebig University Giessen, Giessen, Germany.

Udo Boeken (U)

Department of Cardiac Surgery, Düsseldorf University Hospital, Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH